Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned an average rating of “Hold” from the twenty-six research firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.0909.

Several research firms have recently commented on SRPT. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Citigroup lifted their price target on Sarepta Therapeutics from $9.00 to $13.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Wedbush increased their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research report on Thursday, March 26th.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics during the third quarter worth about $25,000. Ancora Advisors LLC grew its position in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares in the last quarter. Allworth Financial LP grew its position in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Sarepta Therapeutics by 82.5% in the 4th quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 851 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 7.7%

Shares of SRPT traded down $1.57 during trading hours on Friday, reaching $18.95. The stock had a trading volume of 3,025,505 shares, compared to its average volume of 3,717,361. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $25.32. The firm has a 50-day simple moving average of $17.75 and a 200 day simple moving average of $19.29. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -19.74, a P/E/G ratio of 0.20 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.15 million. During the same quarter in the previous year, the business posted ($3.42) EPS. Sarepta Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. Equities research analysts predict that Sarepta Therapeutics will post 3.89 earnings per share for the current fiscal year.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Wolfe Research upgraded Sarepta Therapeutics to outperform and set a $27 price target, signaling meaningful upside potential. Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Outperform at Wolfe Research
• Neutral Sentiment: Piper Sandler trimmed its price target on Sarepta to $20 from $23 but kept a neutral rating, suggesting limited near-term conviction rather than a clear bearish call. Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $20.00 at Piper Sandler
• Negative Sentiment: Broad biotech-sector weakness is weighing on Sarepta and peers like Moderna and ImmunityBio, with investors pulling back after a strong 2026 rally in the group. Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
• Negative Sentiment: Zacks Research downgraded Sarepta to strong sell, adding to the negative sentiment around the stock. Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.